Our Unique Approach
Selonterra develops therapeutics for Alzheimer's disease and Parkinson's disease based on our breakthrough, novel mechanisms on genetics and gene regulatory networks.
Genetics plays a key role in AD and PD. In most cases there is no clear functional link between disease-associated gene variants and disease hallmarks. Consequently, the extensive body of information on disease-associated genes has not translated to therapeutics.
Selonterra's scientists integrate human genetics, molecular pathway analyses and gene regulation to identify disease-causing mechanisms and molecular targets, and exploit these to discover effective therepeutics.
Selonterra's scientists discovered unexpected gene regulatory functions for key Alzheimer's and Parkinson's genes.
Selonterra
Selonterra was founded on the premise that a disruptive approach is required to address unmet medical needs in Alzheimer's disease (AD) and Parkinson's disease (PD).